Vadastuximab talirine is an antibody-drug conjugate (ADC) directed to CD33 (siglec-3) which is a transmembrane receptor expressed on cells of myeloid...

reintroduced to the market in 2017. CD33 is also the target in Vadastuximab talirine (SGN-CD33A), a novel antibody-drug conjugate being developed by...

Utomilumab mab human 4-1BB (CD137) diffuse large B-cell lymphoma Vadastuximab talirine mab chimeric CD33 Acute myeloid leukemia Vanalimab mab humanized...

rovalpituzumab molecule has an average of two such attachments. Vadastuximab talirine, with a similar cytotoxin "Statement On A Nonproprietary Name Adopted...